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The use of vascular stents to treat occluded blood vessels is common practice; 
however, this procedure is often complicated by neointimal hyperplasia reocclusion and 
thrombogenesis. One treatment option is systematically administering heparin to activate 
antithrombin III leading to deactivation of thrombin and other proteases involved in 
blood clotting. This treatment is associated with high rates of bleeding and other vascular 
complications. In addition to the widely known anti-coagulation effects, heparin has long 
been known to exhibit an anti-proliferative effect on the growth of cells. The ideal 
solution would be localized delivery to the site of the interest. Recently, the 
advancements in magnetic resonance have allowed magnetic nanoparticles to be localized 
at sites of interest. We propose that a heparin-coated magnetite nanoparticle will fit this 
ideal solution given it’s potential to deliver localized anti-coagulation and anti-
proliferative effects. In this study, we present the synthesis, characterization, and initial 
cytotoxicity studies of such a particle. 
Magnetite nanoparticles were synthesized and characterized to determine 
magnetic core diameter, hydrodynamic diameter, zeta potential, and heparin loading.  
Live/Dead and MTS assays were utilized to assess cellular toxicity on vascular smooth 
muscle cells (VSMCs). Cellular uptake and actin distribution of VSMCs post 
nanoparticle treatment was observed with Prussian Blue Staining and 
immunofluorescence respectively.  
 iii 
Nanoparticles were characterized by TEM to be in the middle of our target range 
with a diameter of 24.3nm. Heparin loading was found to range from 0.976 to 2.8896 µg 
heparin/µg nanoparticle depending on the synthesis batch. Proliferation and cytotoxicity 
studies on vascular smooth muscle cells showed that at the low loading of heparin on 
nanoparticles, there is indication of proliferation inhibition without VSMC cell death. 
There was not a noticeable cellular uptake of heparin nanoparticles; however, actin 
distribution gives possible indication that VSMCs were induced into their contractile 
phenotype. The results from this study demonstrate a successful synthesis route of 
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The invention of the angioplasty endovascular procedure revolutionized the 
treatment of arterial disease. Unfortunately, this novel treatment was accompanied by a 
new pathology, restenosis, which is the reocclusion of the previously cleared vessel. 
Restenosis is caused by thrombosis and neointimal hyperplasia, the excessive 
proliferation of vascular smooth muscle cells (VSMCs). Treatment options are limited to 
systemic administration of therapeutics or targeted drug delivery through drug-eluting 
stents, with the latter option being the most popular due negative side from systemic 
administration of the drugs. Recently nanotechnology has offered a new drug delivery 
system in the form of magnetic nanoparticles capable of being controlled by a magnetic 
field. 
 The purpose of this research was to determine if heparin, a naturally occurring 
proteoglycan with anticoagulation and antiproliferation properties, has the potential to be 
used in targeted drug delivery via magnetic nanoparticles. Specifically, we aim to 
synthesize a biocompatible nanoparticle with an outer heparin coating. After 
characterizing the properties of the heparin nanoparticle, we performed a series of 
proliferation and toxicity studies to evaluate the feasibility of such a particle in the 
prevention of neointimal hyperplasia 
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1.2 Research Aims 
Aim 1: Synthesize and Characterize a Heparin Coated Magnetic Nanoparticle 
 Biomedical applications of magnetic nanoparticles have very specific size 
requirements to achieve optimal biocompatibility while maintaining the magnetic 
properties that make them desirable. For our pilot study, we synthesized 25 nm magnetite 
nanoparticles and stabilized them with a poly (ethylene glycol) polymer. The 
nanoparticles were functionalized with low molecular weight heparin. Nanoparticle 
characterization included measurement of the magnetic core, the hydrodynamic diameter, 
the zeta potential, and quantification of heparin loading. 
 
Aim 2: Evaluate the Proliferation and Toxicity of Heparin Coated Nanoparticle on 
VSMCs 
 After successful synthesis of heparin coating magnetic nanoparticles, their impact 
on VSMCs was evaluated. We observed the proliferation and toxicity of the particles at 
early stages in treatment. Cellular uptake of particles was observed to estimate the fate of 
the nanoparticle. Inhibition of VSMCs is often accompanied by a phenotypic change; 
therefore, we observed the distribution of α-smooth muscle actin.  
 
1.3 Significance 
 This study describes the first attempt to utilize the natural proliferation inhibitor, 
heparin, bound to a magnetic delivery system for treatment of neointimal hyperplasia. 
The results of this study are indicative for future investigation to determine optimal 
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heparin loading and dosing concentrations. The benefit of such a therapy could change 
the way neointimal hyperplasia is treated. Current treatment methods have major 
drawbacks such as negative systemic side effects and limited about of deliverable drug. 
Magnetic nanoparticles offer a means to deliver as much therapeutic as needed and keep 
the drug localized at the target of interest. The use of naturally occurring heparin has the 
advantage over most synthetic drugs with duel effects in anticoagulation and 
antiproliferation. Such a treatment option is much needed in treating neointimal 
hyperplasia.   
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CHAPTER TWO 
MAGNETIC NANOPARTICLES IN BIOMEDICAL RESEARCH 
 
2.1 Introduction 
 The use of nanoparticles, particularly magnetic nanoparticles, has become a topic 
of great interest for biomedical researchers . Researchers have developed synthesis 
methods allowing the creation of particles with vast range of diameter sizes. Due to their 
size, nanoparticles are able to interact at the cellular and molecular level of biological 
interactions [9].  Magnetic nanoparticles have another advantage in that they obey 
Coulumb’s law allowing manipulation by an external magnetic field. There exist a 
number of potential industrial uses for magnetic nanoparticles including magnetic ink for 
bank checks, magnetic seals in motors, data storage, and biomedical applications [5]. 
Biomedical applications typically require the nanoparticle to have superparamagnetic 
behavior at room temperature, which is characterized by no overall remains of magnetism 
due to a rapidly fluctuating magnetic state [3]. Additionally, the nanoparticle must be 
stable in aqueous solutions at a neutral pH with physiologic salt concentrations.  
 Nanoparticle stability is of upmost importance for biomedical applications; 
therefore, particle size is also of crucial importance. Gravitational forces naturally cause 
nanoparticles to attract and precipitate out of solutions; therefore a stabilization method is 
often employed. Two common methods for stabilization are steric and columbic 
interactions [3]. Steric stabilization methods with a biocompatible polymer are preferred 
for in vivo applications as they hinder biodegradation in addition to preventing 
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nanoparticle aggregation [11]. Particles that meet the above requirements have potential 
for many biomedical applications. In this literature review, we will discuss the 
applications of magnetic separation, targeted hyperthermia, magnetic resonance imaging 
(MRI) contrast agents, and targeted drug delivery.  
 
2.2 Basic Magnetic Concepts 
 Before the applications can be discussed, it is important to have an understanding 
of the basic concepts underlying the desirable properties of magnetic nanoparticles. We 
turn to a review by Pankhurt et al. [12] summarizing magnetic properties as they related 
to magnetic nanoparticles. A magnetic material placed in in external magnetic field, H 
(units: A/m), experiences a magnetic induction of B (units: T) characterized by: 
𝑩 =   𝝁𝟎   𝑯+𝑴          (1) 
where µ0 is the permeability of free space and M is the magnetic moment: 
𝑴 =𝒎/  𝑽           (2) 
where V is the volume of the material and m is the magnetic moment on the volume. 
Furthermore, all materials have some magnetic capabilities depending on the temperature 
and structure of their atoms. This can be represented by magnetic susceptibility, χ, where  
𝑴 =   𝝌  𝑯.         (3) 
The above equation describes the magnetism that is induced in a material by the magnetic 
field, H. χ is a dimensionless quantity, but both M and H are expressed in A/m.  
Paramagnetic or diamagnetic materials display little magnetic ability, and even 
then only under an applied magnetic field. These materials typically have magnetic 
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susceptibilities in the range of 10-6 to 10-1 and -10-6 to -10-3, respectively [3]. Materials 
that display ordered magnetic states even in the absence of a magnetic field are known as 
ferromagnets, ferrimagnets, and antiferromagnets, depending on the interaction of their 
electrons [13, 14]. For magnetic materials, the magnetic susceptibility depends on both 
the magnetic field and the temperature. Due to the saturation of M at large values of H, 
M-H curves are characterized by a sigmoidal curve. Specifically for ferromagnetic and 
ferromagnetic materials, there is an open M-H curve, called a hysteresis loop, due to the 
pinning of magnetic domain calls when they encounter impurities such as grain 
boundaries. Really small magnetic particles, on the order of tens of nanometers, are 
single magnetic domains. This gives the particle as a whole the ability to change in 
response to a field while the individual particles retain their ordered stated relative to 
each other. This unique behavior is known as superparamagmetism. 
It is important to realize that a stable magnetic field will exert torque but no force 
on a particle; therefore, a magnetic field gradient is required to manipulate a magnetic 
particle. The derivation [13, 14] for force starts with the definition of a magnetic force 
acting on a magnetic dipole point: 
𝑭𝒎 =    𝒎   ⋅   𝜵   𝑩     (4) 
which can be expanded to: 
𝑭𝒎 =     𝑽𝒎∆𝝌  𝛁  
𝟏
𝟐
𝑩 ⋅𝑯             (5) 
This equation is the basis for applications such as magnetic separation and targeted 
magnetic drug delivery that will be discussed in the following sections. 
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For nanoparticles used in biological applications, the importance of optimal size 
cannot be underestimated. The particles must be small enough to retain their 
superparamagnetism. Most materials keep this property if the particle is about 5-20 nm in 
diameter [5]; however, nanoparticles for biologic applications must also be large enough 
to avoid rapid renal clearance by the body, which occurs for particles less than 10 nm in 
diameter [15]. Furthermore, nanoparticles with diameters greater than 30 nm are more 
easily filtered by the liver and spleen [16]. Taking all of the considerations into account, 
the working range for most biomedical applications is from 20-50 nm. 
 
2.3 Magnetic Nanoparticle Toxicity 
Magnetic nanoparticles can be made from a variety of metals including cobalt, 
nickel, or iron oxides. Nickel and cobalt are highly magnetic; however, they are also 
easily oxidized and toxic [17]. As such, biomedical applications most commonly 
employee iron oxides, magnetite (Fe3O4) or the more oxidized maghemite (γ-Fe2O3) [15]. 
Bare iron oxide nanoparticles have been shown to result in some cell cytotoxicity; 
however coated iron oxide nanoparticles have also been shown to be relatively 
biocompatible to cells [18]. It has been demonstrated that the cells remain more than 99% 
viable in PEG-coated iron oxide nanoparticles of concentrations up to 1 mg/mL [19].  In 
contrast, uncoated nanoparticles showed a 25-50% loss of viability with concentrations of 
only 250 µg/mL.  High concentrations of approximately 2 mg/mL have been shown to 
lead to high cell viability losses of about 60% [20].   
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 It is thought that the mechanism for iron oxide nanoparticle cytotoxicity is linked 
to cellular update and production of reactive oxygen species.  One study demonstrated 
that P(PEGMA)-immobilized nanoparticles were fairly nontoxic to cells with a 93% cell 
viability [21].  Initially, the particles had a cell viability of 70% over the first two days of 
the study, which increased to 90% by the 5th day.  This led the researchers to suggest that 
the increase in cell viability results from a decrease in the nanoparticle concentration that 
occurs after continued cell uptake of nanoparticles and cell mitosis.  This theory follows 
their results that the uptake of nanoparticles decreased from 154pg/cell on the first day to 
58pg/cell after 5 days [3].  Additional evidence for this theory comes the 93% cell 
viability study, which showed 2pg/cell update giving further support for the belief that 
lower cell cytotoxicity is achieved with reduced of cellular uptake [22].  In one in vitro 
study, several metal oxide nanoparticles were studied at varying concentrations.  It was 
demonstrated that nanoparticles are non-cytotoxic at concentrations below 100µg/mL 
[23, 24].  This result has been replicated by several reports identifying cytotoxic effects 
when nanoparticle concentrations exceed 100µg/mL.  
The number of in vivo human studies are few; however, one study with dextran 
coated iron oxide nanoparticles induced only mild side affects as the iron oxide 
nanoparticles are able to be degraded and cleared from circulation with normal iron 
metabolic pathways [23, 24].  Ability to remove the nanoparticles is greatly impeded 
when nanoparticles agglomerate or which can occur for several reasons.  The 
nanoparticles can interact with each other precipitating out of solution or they can interact 
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with proteins also precipitating out of solution.  In general, the prevention of 
agglomeration, often through a polymer coating greatly improves biocompatibility [3].   
 
2.4 Magnetic Nanoparticles in Magnetic Separation 
 In biomedicine, it is often necessary to separate cells of molecules out of a 
solution. A two step process, shown in Figure 2.1, outlines one solution using magnetic 
nanoparticles: 1) tagging the entity of interested with a magnetic body 2) use of a  
magnetic separate device to pull selectively pick the tagged entity [3]. Tagging of the 
magnetic nanoparticle first requires a biocompatible nanoparticle coating. Dextran, 
polyvinyl alcohol (PVA), polyethylene glycol, and dextran are a few options [25]. In 
addition to stabilization, these polymers provide sites for the attachment of targeting 
molecules such as antibodies or hormones [26]. When added to solutions containing the 
entity of interest, these magnetic nanoparticles will bind to the desired epitope. A 
magnetic field sufficiently strong to immobilize the particle will allow the target to be 
separated from the solution. It should be noted that the magnetic force must be great 
enough to overcome the hydrodynamic drag of the moving solution [28].  
 The ability of a particle to be manipulated by a magnetic field can be described by 
the magnetophoretic mobility. Magnetophoretic mobility increases with particle size; 
therefore, larger particles move faster through solutions. When choosing the application, 
the capability for manipulation will impact the optimal magnetic particle size. For 
example, the experimental time frame for cell manipulations is often relatively short, 
which could benefit from a micro sized particle [29]. Greater particle size comes as a cost 
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as larger particles increase the likelihood of interference with a test post-separation [30, 
31]. After labeling, the process for magnetic separation can be as simple as holding a 
permanent magnetic to the container. This method is commonly limited due to slow 
aggregation rates [30, 31]. More efficient methods can be created with packing a flow 
column with a magnetizable matrix [3]; however, this can lead to problems as the 
Figure 2.1 Illustration of method for removing entities from solution with magnetic 




particles may irreversibility absorb on the matrix. One of the more efficient methods is 
the creation of magnetic field gradients through specific placement of magnets, such as in 
a quadrupolar arrangement in a flow column that creates a gradient radiating out from the 
center [32]. Magnetic separation has found several medical applications including the 
removal of tumor cells from circulation in the vascular system [33]. 
 
2.5 Magnetic Nanoparticles Induce Localized Hyperthermia  
Magnetic nanoparticles subjected to oscillating magnetic fields have shown 
heating capacities resulting from the energy dissipation of the magnetic field reversals.  
This technology has been adapted to various fields including hardening of adhesives, 
development of thermosensitive polymers, and biomedicine [34, 35]. A biomedical 
application of interest is the use of magnetic nanoparticles for induction of localized 
hyperthermia. Seen in Figure 2.2, the treatment consists of dispersing magnetic particles 
throughout the tissue of interest. Applying an alternating magnetic field with sufficient 
strength and frequency will induce heating of the particles, which is immediately 
conducting into the surrounding tissue. Treatment for 30 minutes at a minimum of 42 °C, 
the therapeutic threshold, is enough to destroy cancerous cells [3]. Towards this outcome, 
magnetic nanoparticles have great appeal in that they offer a means to ensure non-
cancerous tissue remains unharmed. 
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Difficult hyperthermia with magnetic nanoparticles first came under investigation 
in 1957 when Gilchrist et al. [36-38] investigated heating various samples with 20-100 
nm iron oxide maghemite nanoparticles under a 1.2 MHz magnetic field. Important 
considerations for clinical treatment include the minimum dose for effective treatment, 
which is complicated due to the presence of blood flow [36-38]. Other important factors 
include the optimization of magnetic field. Both the frequency and magnitude of the 
magnetic field are limited due to adverse physiologic responses at high frequency fields, 
Figure 2.2 Sketch showing general procedure for localized hyperthermia induced by 
magnetic nanoparticles. Created by Andrade et al. 2011 [3] and reproduced in 
accordance to CC BY-NC-SA 3.0 
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which include cardiac stimulation, non-specific tissue heating, and stimulation of muscles 
. Generally it is accepted that magnetic fields can have frequencies of 0.05-1.2 MHz with 
strengths of 0-10 kA/m [40]. 
Since then 1957, there have been multiple in vivo studies, which describe 
methods to achieve the listed requirements and demonstrate the effectiveness of magnetic 
nanoparticle hypothermia [41] including a clinical trial demonstrating a medically 
significant proof of concept [42, 43]. In this study, 14 patients diagnosed with 
glioblastoma multiform, a severe type of brain cancer, were treated with a combination of 
radiotherapy and thermotherapy delivered with aminosliane coated iron oxide 
nanoparticles. Each tumor had multiple injection sites of 112 mgFe/mL magnetic 
nanoparticles with a 15 nm diameter. Tumors were injected with a volume ranging from 
0.1-0.7 mL then exposed to 100 kHz magnetic field with a variable strength field ranging 
from 2.5-18 kA/m [3]. Recently, a magnetic hyperthermia system, NanoTherm® 
developed by MagForce Nanotehnologies (Berlin, Germany) has received approval in 
Europe for treatment of gioblastoma tumors [3]. Based on the recent advances, it is 
possible that magnetic nanoparticle localized hyperthermia may soon see widespread 
clinical use.  
 
2.6 Magnetic Nanoparticles as MRI Contrast Agents 
 MRI has become a vital tool for clinical diagnosis. The underlying concept relies 
on applying an external magnetic field to align protons, such as hydrogen nuclei, in the 
body. Due to the extreme small size of a proton, there may be only three proton moments 
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aligned with the magnetic field (B0 = 1 T) per million proton moments [44, 45]. MRI is 
able to work due to the exceptionally large number of protons in tissues [44, 45]. It had 
been estimated that there are 6.6 × 1019 protons/mm3, effectively making 2 × 1014  
protons/mm3 observable by application of the one tesla magnetic field [46]. As described 
by Pankhurst et al. [47, 48], a proton returning to a disoriented state creates a relaxation 
signal that is measured by the current induced in the scanner coils with equations in the 
form of: 
𝒎𝒛 =𝒎   𝟏−   𝒆
!𝒕
𝑻𝟏      (6) 
and 
𝒎𝒙,𝒚 =𝒎   𝐬𝐢𝐧 𝝎𝟎𝒕+   𝜱 𝒆
!𝒕
𝑻𝟐       (7) 
where T1 and T2 are the longitudinal and transverse relaxation times respectively and Φ is 
a phase constant. The longitudinal relaxation time represents the loss of energy in the 
form of heat to the surroundings. The transverse relaxation is a relatively rapid process 
that occurs due to the magnetic interactions of nearby protons. Dephasing of the system 




∗ =   
𝟏
𝑻𝟐
+   𝜸 𝜟𝑩𝟎
𝟐
              (8) 
where B0 is variability in the magnetic field from the inhomogeneties of the field or local 
fluctuations in the system’s magnetic susceptibility [47, 48].  
 Magnetic contrast agents are often employed to shorten the relaxation time of the 
protons. The most common agents are gadolinium ion complexes; however, 
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superparamagnetic nanoparticles are a viable alternative that can noticeably shorten T2* 
with less of an impact on T1  [3].Iron oxide nanoparticles are the most commonly used 
nanoparticle based contrast agent and exist as regulatory approved, commercial products 
such as Feridex, Endorem, and Resovist [50-52]. Cobalt nanoparticles have an advantage 
over iron oxide nanoparticles in that they have a higher magnetic saturation at room 
temperature [50-52], which may translate to a greater benefit to proton relaxation. The 
major benefit would be the creation of smaller sized particles without compromising MRI 
resolution. Particles smaller than 8nm are easily removed from the body through renal 
clearance [33], which would be an ideal pathway to remove the contrast agent post-MRI.  
Unfortunately, cobalt nanoparticles are significantly limited by the difficulties of 
synthesizing a water-soluble particle without oxidation of the cobalt core. Furthermore, 
the proven toxicity of cobalt sets major roadblocks towards its regulator approval for 
clinical use. 
 
2.7 Magnetic nanoparticles in targeted drug delivery 
 Summarized by Pankhurst et al. [33, 53], most chemotherapeutics have a 
disadvantage in that they non-specific, meaning they will effect a wide variety of entities 
beyond their intended target leading to potential side-effects. This is due in part to the 
method of administration. In cancer treatment, many therapeutics are delivered 
intravenously, which results in a system wide distribution. Non-specific drugs will attack 
normal, healthy cells in addition to the target tumor cells. A similar result may happen 
with use of anti-inflammatory drugs to treat patients diagnosed with chronic arthritis. 
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With no targeted mechanism, high systemic doses of drug are required to achieve the 
needed concentration at the inflamed joint, and many patients are forced off of anti-
inflammatory medications due side effects from the high dosages. 
 In the late 1970’s, researchers proposed targeting sites of interest using magnetic 
carriers controlled by an external magnetic field. The initial studies proposed using 
targeted magnetic drug delivery for cancerous applications [33, 53]; however, other uses 
have since been proposed. The ability to selectively deliver a drug of interest to a specific 
target is applicable to every drug that has an intended effect with an unintended 
consequence for non-specific action. Targeted magnetic delivery begins with the 
coupling of the desired therapeutic to a magnetic carrier, which can be injected into the 
vascular system. Placement of strong magnets around the site of interest pulls the 
circulating carrier to the target for delivery [55], illustrated by Figure 2.3. If the 
therapeutic needs to be decoupled from the carrier, multiple release mechanisms have 
Figure 2.3 Targeted delivery of magnetic nanoparticles to a vascular wall. A) 
depiction of strong electromagnetics placed outside the body B) Close up view of 
directing of magnetic nanoparticles to the walls of an artery. Created by Chorney et al. 
[1][2][6-8][1][1] and reproduced with permission. 
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been suggested including enzymatic activity specific to the target or physiologic 
conditions such a temperature or pH [33, 56-58].  
 Similar to magnetic separation, the effective application requires a magnetic force 
generated by a magnetic field, and efficiency of delivery depends upon the strength of 
magnetic field and magnetic properties of the particles. Additionally, one must consider 
biologic factors such as circulation time, blood flow rate, and biocompatibility of the 
magnetic carrier . Other important parameters include tissue depth as a stronger magnetic 
field gradient would be required to capture particles at a longer distance . Theoretical 
calculations of the parameters needed to successfully produce this type of therapy have 
indicated that there should be a magnetic field gradient around 8 T/m for the femoral 
artery and 100 T/m for the carotid artery . There have been hypothesized models that may 
reduce some of these hurdles. Most notably the use of magnetic needles and meshes has 
modeled magnetic fields and gradients capable of capturing a magnetic nanoparticle in 
circulation . 
 Magnetic nanoparticles have been tested to delivery a variety of drugs both in 
vitro [1] and in vivo [1]. These results indicate the viability of targeted magnetic drug 
delivery. The field still has hurdles such as optimal dosing to overcome before clinical 







 Biocompatibility studies of magnetic nanoparticles have demonstrated non-toxic 
synthesis methods and polymer coatings opening the door to multiple applications. Their 
use has the potential to solve major problems in the medicine such as complications 
resulting from systemic delivery of drugs. As such, the use of nanoparticles has seen a 
huge increase over the past decade and will likely continue to grow as more applications 
move from bench research to clinical trials. 
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VASCULAR SMOOTH MUSCLE CELLS IN NEOINTIAL HYPERPLASIA 
 
3.1 Introduction 
Endovascular surgery revolutionized the treatment of arterial disease with the 
invention of balloon angioplasty. Since its first use in 1977, the primary limitation of the 
procedure has been high rates of restenosis [5]. Restenosis is the narrowing of a vessel 
following surgery to free up blood flow and occurs in a two part process: early 
thrombosis formation and long stage myointimal proliferation [6]. Following injury to the 
vascular wall, there is platelet aggregation to form a clot that obstructs blood flow. 
Fortunately, this dissipates after a few days through normal means; however, it has been 
proposed that the site of thrombosis decides the initiating location of myointimal 
proliferation [7]. The major cause of restenosis results from the proliferation of vascular 
smooth muscle cells (VSMCs) in a process known as neointimal hyperplasia [2]. 
The fate of VSMCs is of great interest to understanding the underlying 
mechanism of neointimal hyperplasia. Described by Melewicz et al. [8], lesions occurring 
in the vascular are characterized by endothelial dysfunction. This allows greater 
permeability of the endothelial cell barrier and leads to an accumulation of lipids and 
oxidation products along the arterial wall.  Intimal cells respond with increased 
expression of adhesion proteins to recruit inflammatory cells to the site for removal of the 
lipids. Attached monocytes become differentiated macrophages and take up oxidized 
lipids leading to the formation of foam cells. The inflammatory response consisting of 
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macrophage recruitment and the production of cytokines, reactive oxygen species leads, 
and mitotic factors leads to other downstream effects. These factors induce the 
chemotaxis of VSMCs from the tunica media into the tunica intima to remodel the 
damaged vessel wall. In this review of literature, we will discuss the different phenotypes 
of VSMCs. Understanding the molecular cues that trigger VSMC migration and 
proliferation is critical to the development of treatment for neointimal hyperplasia. We 
will also address treatments including systemic delivery of pharmaceuticals and drug-
eluting stents.  
 
3.2 Vascular Smooth Muscle Cells 
 Prior to delving into the pathology of neointimal hyperplasia, we must have a 
fundamental understanding the underlying anatomy and physiology of the vascular 
system and VSMCs. In their book, McKinely and O’Loughlin [2] give an excellent 
introduction to of the underlying environment during normal function. The vascular 
system is made up of a large network of interconnected blood vessels whose function is 
to delivery nutrients and remove wastes. The vessels can be broken up into three groups 
based on the physiologic structure: arteries, veins, and capillaries. Arties and veins can be 
further broken down into three layers/tunics: intima, media, and externa.  
 The tunica intima is composed of a single layer of squamous endothelial cells, 
with a subendothelial lining of connective tissue. The main function of the tunica intima 
is to create a smooth, non-thrombogenic surface over which blood can flow. The tunica 
media is mainly made up of VSMCs but also contains a significant amount of 
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extracellular matrix such as collagen (types I, III, and V), elastin, and proteoglycans. 
Through VSMCs contraction and relaxation, the tunic media can modulate vessel 
diameter with the goal of maintenance of steady blood flow. The outermost layer, tunica 
externa, is mainly composed of a protein matrix used to anchor blood vessels  to 
surrounding tissue. The three tunics can be found in all arties and veins; however, there 
will be slight differences depending on physiological location.  
VSMCs have a unique ability to alter their phenotype after the developmental 
period of growth is over, such as in response to vascular injury leading to remodeling of 
Figure 3.1 Overview of phenotype switching differences between VSMCs. The depiction on 
the left represents the dedifferntiated, synthetic VSMC phenotype, whose main purpose is to 
repair damaged vasculature. The quiescent, contractile phenotype is shown on the right with 
the defining features of organized contractile fibers spanning the cell.  
 
Original work by Milewicz et al. [4]Reprinted by permission from Macmillan Publishers Ltd 
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the damaged vessel [9]. Under normal conditions, VSMCs remain in their quiescent, non-
proliferative phenotype. This is often called their contractile phenotype due to the 
expression of myofilaments containing contractile proteins such as α smooth muscle 
actin, β myosin heavy chain, calponin, and smoothelin [10]. These filaments are aligned 
into contractile apparatuses giving the VSMC a spindle shape. In response to injury, 
VSMCs reduce the expression of contractile protein genes;  scientists often use this gene 
Figure 3.2 Signaling pathways to initiate or maintain SMC differentiation. Abbreviations: 
DRF indicates diaphanous-related formin; Mech, mechanical; FRNK, focal adhension kinase 
(FAK)-related nonkinase; TβRII, type II TGF-β receptor; NFkB, nuclear factor κB; MHC, 
myosin heavy chain; RGS, regulator of G-protein signaling; Col, collagen; Lam, laminin; 
AT1, angiotensin II receptor 1; IGF, insulin-like growth factor; Jag, jagged; Dll, delta-like; 
MAML, mastermind-like; MyoC, myocardin; Lpxn, leupaxin; P, phosphorylation; TK, 
tyrosine kinase  
Original work by Mack 2011 [1][2][5][6-8][1][2][5][6-8][1]. Reproduced by permission from 
Wolters Kluwer Health, Inc.  
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expression to determine the differentiated state of VSMCs [2]. In the dedifferentiated 
state, VSMCs proliferate, secrete enzymes to digest the extracellular matrix, and 
synthesize a new extracellular matrix all in an attempt to repair the injured tissue. 
VSMCs portraying these characteristics are termed to be in the synthetic phenotype [11, 
12]. The differences in the VSMC phenotype are summarized in Figure 3.1. 
 Much work has been done to determine what are the underlying molecular signals 
that could be used to initiate or maintain the synthetic phenotype. What is known about 
the pathways  that induce VSMC differentiation can be seen in Figure 3.2. Pathways that 
Figure 3.3 Signaling pathways that promote VSMC phenotypic switching. Abbreviations: AII 
indicates angiotensin II; PDGFR, PDGF receptor; Inflamm, inflammation; BMP, bone 
morphogenetic protein; BMPRII, bone morphogenetic protein receptor II; TK, tyrosine 
kinase; HDAC, histone deacetylase; Ub, ubiquitin; TCF, ternary complex factor.  
Original work by Mack 2011 [2]. Reproduced by permission from Wolters Kluwer Health, 
Inc.  
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promote VSMC phenotypic switching can be seen in Figure 3.3. Understanding the 
molecular mechanisms of VSMCs is crucial to one day be able to induce a desired 
VSMC phenotype on command.  
 
3.3 Treatments for Neointimal Hyperplasia 
 One of the first prospects to treat neointimal hyperplasia was systemic delivery of 
drugs. Very closely following the invention of balloon angioplasty and the subsequent 
identification of restenosis complications, many compounds were evaluated to treat this 
disease. Unfortunately, most of the drugs that have been investigated are only effective at 
narrow dosing ranges and have poor toleration when administered systemically [11, 12]. 
The next developmental phase focused on the invention of local drug delivery system 
allowing a high dose of therapeutic to be delivered to the artery of interest without 
exposing the entire body to the adverse effects. These delivery systems were found to be 
able achieve drug concentrations 400 to 1000 times greater than a non-specific systemic 
administration of the same compound [13-16]. Currently, there exist four main options 
under investigation for the prevention of neointimal hyperplasia: drug eluting stents, duel 
drug eluting stents, drug eluting balloons, and porous balloons [3]. The major advantages 
and disadvantages of each group are listed in Table 3.1.  
 The U.S. Food and Drug Administration approved drug-eluting stents in 2003 for 
treatment of coronary artery disease [17]. Over short term time periods, DESs show a 
significant reduction in neointimal hyperplasia compared to bare-metal stents [3]. There 
have been a variety of clinical trials testing different therapeutics with DESs including 
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sirolimus, everolimus, and paclitaxel [3]. While they have been readily received adaption 
into clinical use, there remain a few major hurdles to overcome. Notably, there is the 
matter of limited drug delivery due to the small surface area and poor outcomes in 
peripheral arteries.[18]  
 Other areas of research include bioresorbable stents, which are designed to 
provide temporary support and restoration of vessel wall. With time, the entire stent will 
dissolve leaving only fully healed native tissue. Several major advantages to bioresorable 
stents include ability of vasculature to maintain native tone [3], the freedom to preform 
later surgical revisions [18], use in pediatric patients [19], and use in patients with metal 
allergies [3]. Metal alloy bioresorbable stents, particularly magnesium, have advantages 
over polymers due to the increased strength, more rapid degradation, and minimal 
inflammatory responses [20]. Magnesium is the material of choice due to a 4-month 
degradation time and the capacity for incorporation in the body’s natural mineral supply. 
The evaluation of bioresorbable stents is currently in progress and in need of a large 
randomized clinical trial to access efficiency over DESs. 
 
3.4 Heparin as a Drug 
 Heparin is a naturally produced glycosaminoglycan (GAG) that is synthesized by 
mast cells in connective tissue and stored in cytoplasmic secretory vesicles [21]. Heparin 
was discovered nearly 100 years ago and should not be confused with heparin sulfate. 
Discovered as an impurity in heparin, heparin sulfate is synthesized and expressed by 
nearly all mammalian cells and has a variety of biological functions [20]. Both heparin 
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and heparin sulfate and constructed from the same repeating 1-4 linked monosaccharide 
blocks of uronic acid and D-glucosamine. There 24 common variations of the uronic 
acid/glucosamine disaccharide that comes from differences in the functional groups on 
the monosaccharide building blocks. The defining difference between heparin and 
heparin sulfate is in the proportion of disaccharides [22]. 
Since heparin’s initial use as an anticoagulant in 1935, it has become one of the 
most used natural therapeutics, second only to insulin [23]. Heparin inhibits thrombin and 
activated coagulation factors IX, X, XI, and XII [21, 22]. In addition, heparin inhibits 
proliferation of VSMCs independently of its anticoagulation effects [21, 22]. It was 
shown that treatment with heparin leads to increase expression of differentiated VSMC 
markers such as α-smooth muscle actin and calponin [21, 22, 25, 26]. Animal studies in 
rats studies demonstrated that sustained systemic injections of heparin can lead to 40-
50% reduction in neointimal thickening [21, 22, 25, 26]. However, the systemic delivery 
of heparin in humans was reported to result increased rates of internal bleeding [23, 28].  
An alternative approach is through heparin-coated stents, which have shown encouraging 
results supporting the use of localized delivery of heparin [23, 28]. As both an anti-
coagulant and VSMC proliferation inhibitor, heparin remains a drug of interest in the 
prevention of neointimal hyperplasia. 
 
3.5 Conclusions 
Neointimal hyperplasia remains one of the major complications associated with 
endovascular and vascular surgery. The underlying cause is the proliferation of VSMCs, 
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which in response to vascular injury undergo a phenotypic shift to repair the integrity of 
the wall. In the past few decades, there has been significant progress towards preventing 
this disease with the widespread clinical use of drug-eluting stents; however, there still 
remain unsolved problems. New prospects, such as the localized delivery of natural 
proliferation inhibitors, may be able to improve clinical outcomes.   
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Table 3.1 Summary of common investigated options for localized drug delivery  
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Magnetic nanoparticles have potential for use in a wide variety of fields. One advantage 
to magnetic nanoparticles it their controllability with an external magnetic field making 
them an excellent choice for targeted drug delivery. Heparin is the drug of interest for this 
study and has long been known to inhibit proliferation of vascular cells. It has been 
suggested for use in treating neointimal hyperplasia to slow vascular smooth muscle cell 
growth. Localized heparin delivery approaches have shown promise. Therefore, the 
purpose of this study is to synthesize and characterize a heparin coated magnetic 
nanoparticle for targeted delivery.  
Materials and Methods: Magnetite nanoparticles were created using thermal 
decomposition of iron acetylacetonate and oleic acid. Poly (ethylene glycol) was used for 
steric hindrance stabilization. Nanoparticles were characterized using TEM, FTIR, 
hydrodynamic diameter, zeta potential and DMMB assays. 
Results: A uniform distribution of nanoparticles was synthesized with a diameter of 24.3 
+1.9 nm.  Analysis of DLS results indicated that the PEG polymer successfully replaced 
the oleic acid surfactant. Variability among nanoparticle batches led to a heparin loading 
from 0.1056 to 3.1 gram of heparin per gram of nanoparticle. 
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Conclusions: These results indicate the successful synthesis of heparin-coated 
nanoparticles; however, variability among batches suggests that the process requires 
further investigation for refinement. 
 
4.2 Introduction 
Magnetic nanoparticles have great interest for researchers due to their potential 
for use in a wide variety of applications due to their responsiveness to a magnetic field. 
They have already seen use in many disciplines including the creation of magnetic fluids, 
data storage, and biomedicine [2].  In particular superparamagnetic nanoparticles have 
high potential for multiple biomedical applications including hyperthermia, magnetic 
resonance imaging, tissue repair, targeted drug delivery, and cellular therapy [3, 4].  Most 
applications require the size of the nanoparticle remain below a critical value, typically 
around 20nm [5]. One major hurdle in the development of nanoparticles is controlled 
synthesis to achieve this optimal particle size. 
There exist multiple methods to synthesize magnetic nanoparticles. Depending on 
the desired outcome, researchers may choose an efficient method to produce highly 
stable, shape-controlled and monodisperse magnetic nanoparticles. Popular methods are 
hydrothermal synthesis, microemulsion, co-precipitation, and thermal decomposition [2]. 
Thermal decomposition was inspired by the synthesis of high-resolution nanocrystalline 
semiconductors [6] and is of  particular appeal for biomedical applications due to the 
ability to achieve nanoparticles with a monodisperse size and shape. Typical synthesis 
occurs with the thermal decomposition of organometallic precursors such as metal 
acetylacetoneates [7] in organic solvents with high boiling points such as fatty acids [8] 
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or hexadecylamine [9]. Changing the starting ratios of the organometallic compound and 
surfactant controls nanoparticle size and shape. Fine tuning of the these properties is 
achieved by controlling the reaction time and reaction temperature [2]. Using the thermal 
decomposition method, monodisperse Fe3O4 nanocrystals with diameters ranging from 3-
50 nm have been created demonstrating the effectiveness and versatility of the method 
[10]. There exist several material choices for the synthesis of magnetic nanoparticles 
including iron, cobalt, and nickel [2]. For biomedical applications, iron oxides, such as 
magnetite or maghemite, have proven to be superior to alternative options due to 
increased biocompatibility and stability [5, 11-13]. From here on, we will refer to iron 
oxide magnetic nanoparticles when discussing magnetic nanoparticles. 
The importance of narrow size distribution is of critical importance to the 
functionality of the magnetic nanoparticle. The ideal range for magnetite is around 5-20 
nm [5]. At this size, each nanoparticle behaves as a single magnetic domain displaying 
superparamagnetic behavior. Smaller particles have greater tendency to not agglomerate 
due to their smaller magnetic moments, so the magnetic force between particles is 
reduced. Typical stabilization methods can be broken down into two major groups: 
electrostatic repulsion or steric hindrance. There exist multiple steric strategies that all 
end up with a similar outcome, a magnetic nanoparticle core inside of a protected by a 
shell structure that physically blocks neighboring particles from sticking together. The 
common mechanisms for protection include coating with surfactants[14], polymers[15, 
16], silica [17], carbon [18], or precious metals [19]. Some of most investigated polymer 
coatings are dextran, starch, chitosen, polyethylene glycol (PEG), and polyvinyl alcohol 
(PVA) [20]. Besides being used for steric hinderance, some of these polymers can be 
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used for attachment of additional targeting ligands for biological targeting. In general, for 
biological applications, hydrophilic polymer coatings have a significant advantage 
providing greater biocompatibility [21] and allowing the option for additional 
modifications to add functionality. 
One such possibility for added functionality is the biological molecule, heparin. 
Heparin is a small linear glycosaminoglycan that is commonly used as an anti-coagulant 
[22]. In addition to anti-coagulation, the medical community has known for decades of 
the anti-proliferative effects of heparin [23, 24]. Early clinical trials of systemic heparin 
administration to prevent neointimal hyperplasia proved to be ineffective [25] with an 
increase in minor bleeding [26]. However, localized delivery of heparin has been shown 
to be effective at decreasing vascular smooth cell proliferation without increased internal 
bleeding risk [27].  Biocompatible magnetic nanoparticles conjugated with heparin could 
provide a novel targeted heparin therapy; magnetic fields could be used to keep the 
heparin particles localized to the sites of interest. Here, we describe the synthesis and 
characterization of heparin-coated iron oxide magnetite nanoparticles using the thermal 






4.3 Materials and Methods 
Synthesis 
Magnetite nanoparticles were synthesized using the a modified version of Sun’s 
method [28]. For this study, iron (III) acetylacetonate (Fe(acac)3) (Fluka) was used as the 
iron precursor and oleic acid was employed as the ligand. Using previous work to aim for 
a target nanoparticle diameter of 25 nm, we combined Fe(acac)3  with oleic acid (Alfa 
Aesar) in a 1:15 molar ratio. As an example, 1.078g (3 mmol) of Fe(acac)3 was combined 
Figure 4.1 Chemical synthesis mechanisms for heparin coated 
magnetite nanoparticle  
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with 13.48g (47.6 mmol) of oleic acid in a three-neck round bottom flask. The reaction 
took place under flowing nitrogen at 0.1 liter per minute while stirring with an overhead 
stir bar. The solution was heated up to the refluxing temperature of 360 °C and held there 
for one hour.  
  The reaction solution was then allowed to cool to room temperature. The 
resulting product was suspended in hexanes to transfer to centrifuge tubes and was 
washed three times by precipitation with acetone followed by resuspension with hexanes. 
After the final wash, the nanoparticles were left in a drying oven for two days to remove 
remaining traces of solvent. The dried particles were suspended in tetrahydrofuran (THF) 
(Fisher Scientific) and further purified using THF gel permeation chromatography (GPC) 
of Bio Beads S-X1 Support (Bio Rad 152-2151) packed in a glass column (40 cm long, 
2.5cm diameter) and pressurized with 5 psi N2 gas. Nanoparticles were either 
immediately used in a ligand exchange or kept in THF for long-term storage 
Figure 4.2 PEG polymer used in ligand exchange to stabilize the 




Use of nanoparticles in biological applications requires hydrophilicity; therefore, 
the previously described hydrophobic particles were modified with a hydrophilic ligand. 
Previously, our lab has synthesized and characterized a hydrophilic polymer consisting of 
nitroDOPA anchors attached to 1,800 g/mol poly (acrylic acid) (Sigma-Aldrich) with a 
8,000 g/mol poly (ethylene glycol) (Sigma-Aldrich) spacer terminated in an alcohol, seen 
in Figure 4.2. We used excess polymer (250mg) dissolving it in 5 mL chloroform (Fisher 
Scientific) and back filling with inert nitrogen gas. From the particle synthesis, we 
removed the THF solvent by rotary evaporation. The product was suspended in 5mL of 
chloroform and added drop-wise to the polymer solution over 15 minutes while under 
sonication.  The resulting reaction was placed on a shake plate and agitated for 7 days. To 
remove unreacted polymer, the post-reaction product was run through a THF GPC.  
 
Modification with Heparin 
In order to attach heparin, polymer modification was required to change the 
terminal alcohol to an amine group. The reaction was preformed under a nitrogen gas 
blanket. Excess 3-chloropropylamine (Sigma) was dissolved in 5 mL of dichloromethane 
(DCM) (Acros Oragnics). Triethylamine (Fisher Scientific), utilized as a scavenger for 
acid, was combined with the 3-chloropropylamine in molar ratio 1:3. The nanoparticle 
mixture was added drop-wise into the reaction. The reaction was placed on a shake plate 
and agitated for 2 days.  
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 Carboxylic acid groups of heparin were covalently bonded to the primary amine 
groups on the nanoparticle ligand using standard EDC/NHS chemistry. The concentration 
of nanoparticle solution was determined with an iron determination assay leading to the 
calculation of the number of free ligands in solution. Molar ratios of 1 ligand : 3 heparin 
(MW 3000g/mol, MP Biomedicals) : 30 EDC (TGI) : 65 sulfo-NHS (Thermo Scientific) 
were dissolved in deionized water. Heparin, EDC, and sulfo-NHS were combined and 
allowed to equilibrate for 15 minutes before adding the nanoparticle mixture. The 
reaction was allowed to proceed for 12 hours at room temperature. Heparin coated 
nanoparticles were purified by running through a water column. The proposed 
synthesized nanoparticle can be seen in Figure 4.3..  
Figure 4.3 Proposed synthesized heparin nanoparticle  
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Characterization 
 Following the initial synthesis reaction, transmission electron microscopy (TEM) 
was used to measure the size distribution of the nanoparticle solution. Diluted (~0.1mg 
Fe3O4 per mL) hexane solution was dropped onto a copper grid coated with a carbon film. 
Using a Hitachi H-9500 instrument with an accelerating voltage of 300 kV, high 
resolution images were obtained at 200, 000X and 600, 000X. Using the Feret’s diameter 
function from ImageJ’s particle analysis, approximately 300 nanoparticles were measured 
to determine the size distribution. Before and after the addition of the terminal amine, 
Fourier transform infrared spectra (FTIR) was taken by Thermo-Nicolet Magna 550 
FTIR to confirm the presence of a primary amine with peaks of 1580-1650 cm-1 and 
3320-3520 cm-1. 
 At each step in the synthesis of heparin coated nanoparticles, dynamic light 
scattering (DLS) was used to estimate the hydrodynamic diameter. Measurements were 
made in dH2O with a Malvern Zetasizer NanoZS. We report the intensity-weighted sizes. 
Zeta potential is defined to be the electric potential at a small distance from the surface of 
the particle (i.e. the slipping plane) relative to a point far away in solution. For 
simplification, it can be thought of as the potential difference between the 
electrostatically bound fluid and the dispersive fluid. As an important parameter to 
understand the colloidal stability through electrostatic charges, zeta potential at the 
various stages was carried out also using capillary cell electrophoresis technique and the 
Zetasizer NanoZS.  
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Iron Determination Assay 
 A modified previously described method [29] was used to find the concentration 
of iron in solution. For the full descriptive protocol, see Appendix A. In short, working 
solutions of 100 g/L of hydroxylamine hydrochloride (Sigma-Aldrich) in deionized water 
(dH2O), 3 g/L of 1,10-phenanthroline (Sigma-Aldrich) in 10% methanol (Honeywell 
Burdick and Jackson) diluted with dH20, and 100 g/L sodium acetate  (VWR) in 20% 
glacial acetic (Mallinckrock Chemicals) acid diluted with dH2O. A standard curve was 
created from the dissolved iron and developed by successive additions of hydroxylamine 
hydrochloride, 1,10-phenanthroline, and sodium acetate-acetic acid. Background 
absorbance, read at 690 nm, were subtracted from sample absorbance read 511nm with a 
Figure 4.4. Schematic of ions away from a particle and 
resulting electrical potential as a function of distance from 
the particle surface. Taken from  
http://en.wikipedia.org/wiki/Zeta_potential and reproduced 
in accordance to CC BY-SA 3.0  [5] 
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UV-Vis spectrophotometer. Using the nanoparticle diameter from TEM analysis, density 
(5.2 g/cm3) of magnetite [30], and volume of solution, the concentration of nanoparticle 
solution was calculated 
 
Dimethyl Methylene Blue Assay 
Glycosaminoglycans are long unbranched polysaccharides that are made up of a 
repeating disaccharide unit consisting of a hexosamine (glucosamine or galactosamine) 
and a hexuronic acid (glucuronic or iduronic acid). A previously described method [31, 
32] describes the method for quantification of sulfated GAG content using the 
colorimetric indicator, 1,9-dimethylmethylene (DMMB) (Sigma), which undergoes a 
shift in its absorption spectrum when bound to sulfated GAGs. DMMB assays were used 
to quantify the amount of heparin attached on the nanoparticles and confirm the success 
of heparin attachment. 
 Using a round-bottom 96 well plate, 180µL of DMMB solution was added to 
20µL of sample. Standard curves 0-100µg/mL) of heparin and chondroitin sulfate 
(Sigma) were found to not be significantly different (see Appendix C). Samples were 
agitated for 5 seconds, and the absorbance at 530nm was immediately read using a 
microplate reader. The coating of heparin/nanoparticle was determined using the 
measured DMMB absorbance, the linear regression equation, and the concentration of 





Analyzing the TEM images (Figure 4.5), it is evident that the synthesized 
nanoparticles form a uniform distribution. The average diameter was found to be 24.3 ± 
1.9 nm. This value was significantly lower than the dynamic light scatting estimated 
hydrodynamic diameter of 64.43 nm. Following the ligand exchange of oleic acid for 
nitroDOPA-PAA-PEO-OH the hydrodynamic diameter was notability increased to 150.1 
nm. Ensuring polymer modifications led to slight hydrodynamic diameter decreases first 
to 149.1 nm following the 3-chloropropylamine reaction replacing the terminal alcohol 
with a primary amine group. After the EDC/NHS reaction attaching heparin to the 
nanoparticle, we saw a dip down to a hydrodynamic diameter of 131.6 nm. 
Figure 4.5 TEM Results a) TEM image of uncoated iron oxide particles. b) Histogram 
of nanoparticle magnetic core diameter 
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Figure 4.6. FTIR spectrum after addition of terminal amine group to polymer 
Figure 4.7 Dynamic light scattering hydrodynamic diameters of particles 
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After replacement of the oleic acid ligand with the PEO polymer, the reaction was water-
soluble and zeta potential measurements were taken at subsequent steps. The zeta 
potential of the PEGylated nanoparticles was found to be -0.809mV. Addition of the 3-
chloropropylamine led to an increase up to a zeta potential of 1.07mV. Following the 
EDC/NHS chemistry, the zeta potential dropped to -3.74mV.  
After the EDC/NHS attachment of heparin, the product was purified by running it 
through a water column. The output was collected in 5mL fractions. Fractions that 
contained nanoparticles were determined by the presence of a brownish tint color seen in 
fractions three to nine of Figure 4.8. Positive DMMB assays of tinted fractions confirmed 
both the success of heparin nanoparticle synthesis. The purification profile can be seen in 
Figure 4.8 showing the concentration of heparin determined by a DMMB assay. The 
distribution shows a distinctive bimodal shape indicating both the attachment of heparin 
and the purification of the nanoparticle were successful. 
Table 4.1 Summary of hydrodynamic diameter and zeta potential 
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The theoretical loading of heparin on a nanoparticle was calculating using the 
diameter from TEM analysis and the assumption of 5 free ligands/nm2. This value was 
determined to be approximately 1.2 grams of heparin per gram of nanoparticle 
(approximately 9400 heparin molecules/nanoparticle). The actual loading heparin was 
determined using a combination of an iron determination assay and DMMB assay. 
Shown in Figure 4.9, three concentrations of nanoparticles were measured using the 
DMMB assay and fitted with linear regression to return the slope value of 2.889 
heparin/µg nanoparticle (approximately 22,500 heparin molecules/nanoparticle). We also 
show the lack of GAGs on the control nanoparticle. The heparin loading was repeated on 
Figure 4.8 Purification profile of heparin nanoparticles, measured with DMMB assay, after 
running through water column. 
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 4.5 Discussion 
Magnetic nanoparticles have a wide variety of applications; however, the 
properties depend upon the size meaning that a narrow size and shape distribution is of 
upmost importance for tailoring to specific applications [33]. For most envisioned 
applications, researchers typically desire to have nanoparticle diameters in the 10-50nm 
range [2].  In our synthesis, our goal for optimal nanoparticle range was 20-30 nm for 
increased circulation time. Particles must be larger than 10 nm to avoid rapid removal by 
the kidneys [34, 35]. However of the nanoparticles large enough to avoid renal clearance, 
it has been shown that larger particles are easier to remove [36, 37]. In addition, larger 
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Figure 4.9 Determination of heparin loading on nanoparticles by iron assay and 
DMMB assays 
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size particles lose the capacity for superparamagnetic behavior [2], leaving the ideal size 
for targeted heparin delivery to be in the 20-30 nm range. As seen in 4.3, it is evident that 
we have achieved a uniform distribution directly in the center of our target range. 
Due to the use oleic acid as the surfactant for the synthesis, nanoparticles 
immediately resulting from the reaction are hydrophobic. Biological use requires the 
solubility in aqueous solutions justifying our ligand exchange. As a biocompatible 
hydrophilic polymer, PEG coatings have been seen wide spread use through the medical 
field in a variety of applications [21]. In addition to improve biocompatibility, the use of 
a PEG brush provides stabilization to our particles prevent agglomeration through steric 
hindrance.  Multiple studies have sought to take advantage of this double benefit [38, 39].  
As part of a verification step, FTIR was used to confirm the presence of primary 
amines following the modification step of the PEG polymer with 3-chloropropylamine. It 
is known that primary amines display a small to medium peak with a wavenumber in the 
range of 1580-1650 cm-1 and also at 3320-3520 cm-1 [40], marked in Figure 4.6. This 
result was interpreted as successful modification, and the synthesis proceeded to next step 
with heparin attachment. 
The bonding of heparin was verified with two methods: measurement of zeta 
potential and DMMB assay. The zeta potential was measured at the three polymer 
modification steps during the synthesis. Following the ligand exchange, we measured a 
zeta potential of -0.809 mV, which is consistent with other work showing PEG coated 
nanoparticles to have an approximately neutral zeta potential [41]. Following the addition 
of a primary amine, we noted an increase in zeta potential to 1.07 mV. This also a 
consistent change following modification with a primary amine [42]. Finally, heparin 
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modification led to a decrease in zeta potential down to -3.74 mV. As heparin has one of 
the highest negative charge densities of known biological molecules [43], it is 
unsurprising that the addition of heparin leads to a decrease in zeta potential. This was 
used as verification to confirm the successful modification of heparin to the nanoparticle. 
Studies with other heparin-coated nanoparticles have shown zeta potentials ranging from 
-10 to -40 mV [44, 45]. Additionally, the smaller magnitude zeta potentials of our 
particles is likely due to the polyethylenimine brush coating as  the use of a brush coating 
of polyethylenimine for steric stabilization has been shown to result in particles with a 
more positive surface charge [44] 
The combination of iron determination and DMMB assays were used to quantify 
the loading of heparin onto the magnetite nanoparticles. Two different batches of heparin 
nanoparticle synthesis underwent quantification, shown in Figure 4.9. It is evident that 
the process is very batch dependent with the first batch testing yielding 2.889 ug heparin / 
ug nanoparticle, while the second batch was loaded at 0.976 ug heparin / ug nanoparticle. 
This is close to a 3-fold difference in the concentration and could have potential for larger 
impact on the biological level. Batch differences may be due to problems that occurred 
when the synthesis method used to create the high loaded group was scaled up, which 
resulted in the low loading batch. While the ratios of the reactants were kept constant 
between synthesis batches, the reactant concentrations were increased by approximately 5 
times in the scale up while maintaining the same volume. As an negatively charged 
molecule at pH values greater than 3 [46], heparin has a natural electrostatic repulsion for 
itself, which may have resulted in a lower loading when the reaction concentration was 
increased. 
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It is this same the localized charge density from binding so many heparin 
molecules in close proximity that we believe plays a major role in the cellular response 
that we observed in the next chapter. 
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CHAPTER FIVE 
EFFECTS OF HEPARIN-COATED MAGNETIC NANOPARTICLES ON 
VASCULAR SMOOTH MUSCLE CELLS 
 
5.1 Abstract 
Purpose: Neotintimal hyperplasia is one of the main problems facing endovascular 
surgery. Nanoparticles, which induce a vascular smooth muscle cell (VSMC) phenotypic 
shift towards the quiescent contractile phenotype, would have a huge impact on the 
treatment of patients after endovascular surgery. In pursuit of this, we have developed a 
heparin-coated nanoparticle. This study describes the in vitro testing of heparin-coated 
magnetite nanoparticles on VSMCs.  
Materials and Methods: VSMCs were treated with 0-100µg/ml concentrations of 
heparin-coated nanoparticles. Cell toxicity was measured with MTS and Live/Dead 
assays. The cell morphology changes in response of the nanoparticle were characterized 
with Prussian Blue Stain and immunofluorescence staining of alpha smooth muscle actin 
fibers. 
Results: We observed inhibition of proliferation of VSMCs in a dose dependent fashion 
with noticeable changes in cell number occurring at doses as low as 1 µg/mL. 
Observation of alpha smooth muscle actin fibers suggested possible alignment of fibers 
indicative of VSMC phenotype change. 
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Conclusions: Toxicity/proliferation studies indicated that heparin nanoparticles have 
potential for use in the clinic. Further investigation is required towards the optimal dosing 
and further characterization of VSMC markers characteristic of the contractile phenotype. 
5.2 Introduction 
 Presently, one of the major problems facing vascular surgery is neointimal 
hyperplasia, caused by the excessive proliferation of vascular smooth muscle cells.  
During neointimal hyperplasia, VSMCs loose contractile proteins, while increasing their 
proliferation, production of extracellular matrix, and migration [1]. This process 
describes a shift from the contractile phenotype towards the synthetic/proliferative 
phenotype. The defining feature of the contractile phenotype is the presence of a 
contractile apparatus containing smooth muscle α-actin, smooth muscle myosin heavy 
chain, calponin, and SM-22 [1, 2]. Of these proteins, smooth muscle α-actin is the most 
commonly used marker of differentiated lineage. 
 Heparin has been shown to inhibit proliferation of VSMCs both in vitro and in 
vivo [3-6].  While this effect has known for some time, there still remains much unknown 
about the exact mechanism through which heparin takes action. It is known that heparin 
can be internalized [7] through cell surface heparin sulfate proteoglycans [8]. 
Furthermore, heparin can activate protein kinase R, which leads to blocking of the G1 to 
S-phase transition of the cell cycle [9]. Alterative suggested mechanisms include the 
interaction with an unknown surface receptor leading to activation of protein 
phosphatases that can modulate the cell cycle progression [10-12]. The degree of 
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sulfation impacts the anti-proliferative properties; however, no critical structural motif or 
sulfate location seems to be the responsible party for heparin’s effects [13-17]. 
Superparamagnetic iron oxide nanoparticles (SPIONs) are of particular interest 
for biomedical applications requiring a magnetized particle, due to their reduced 
cytotoxicity and stability compared to other magnetic nanoparticles [18-21]. Depending 
on the study, bare metal SPIONs exert some toxic effects when treated at concentrations 
ranging from 50-250 µg/mL [18]. Coating the nanoparticle with a biocompatible polymer 
can reduce the toxicity. It has shown that coating with poly (ethylene glycol) allowed 
cells to remain 99% viable at a concentration as high as 1mg/mL [22]. Overall, it is very 
hard to determine the viability and optimal dosing of a nanoparticle before cellular 
testing, partially because nanoparticle concentrations and sizes vary widely in the 
literature during toxicity testing. Further complicating the issue is the fact that different 
research groups have tested their particles on a many different cell lines. 
The first step in understanding a potential treatment effect in the body is in vitro 
cellular studies as they allow researchers to control experimental conditions. Cells are 
sensitive to fluctuations in nutrients, waste concentrations, pH, and temperature [23], 
which allows researchers to focus in on the underlying mechanism of cellular responses. 
Therefore, cellular testing is ideal for testing of nanoparticle toxicity and characterization 
of the mechanism through which the particle exhibits its effect giving researchers 
validation of potential treatments before ever testing in the body. 
One of the simplest means to assess cellular condition is qualitative observation 
through bright-field microscopy. This technique can be useful in assessing toxicity when 
 63 
there is a noticeable change in cell or nuclear morphology [24]. However, the more 
common method is a quantitative assay that assesses cell viability through a colorimetric 
change. Different quantitative tests have been developed to test various cellular functions. 
Common tests include the Live/Dead viability test [25], lactate dehydrogenase release 
monitoring [26-28],and MTT/MTS viability assays [29, 30], which test for intact cellular 
membranes, number of damaged/dead cells, and metabolic activity respectively. 
 This study describes the merge of nanotechnology with the antiproliferative 
effects of heparin. Using the heparin-coated nanoparticles from Chapter Four, their 
potential for use in treatment of neointimal hyperplasia is evaluated through toxicity 
studies on VSMCs and characterization the mechanism of action at early time points.  
 
5.3 Materials and Methods 
Cell culture 
Aortic vascular smooth muscle cells were isolated from adult Sprague Dawley 
rats with the protocol described in Appendix D. The rat VSMCs were cultured in High 
Glucose Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco) supplemented with 
10% fetal bovine serum (Atlanta Biologicals) and 1% penicillin/streptomycin (HyClone). 
VSMCs were grown to 70-80% confluence in T-75 flasks at 37°C and 5% CO2, replacing 
cell culture media every 48 hours. Cells were passaged using 0.25% trypsin with 0.02% 





 Heparin coated nanoparticles (NP-Hep) were synthesized and characterized as 
described in Chapter Four. The amine terminated particle (NP-NH2) from the last step 
before addition of heparin through EDC/NHS chemistry was used as a control particle 
throughout all testing. 
 
MTS Assay 
 The proliferation of cells was measured using the CellTiter AQueous One Solution 
Cell Proliferation Assay kit (Promega). The detection of viable cells is based on the 
capacity of cells to reduce the MTS tetrazolium compound, [3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, into a colored formazan 
product that is soluble in cell culture media. Cells were seeded at 2,000 cells/well into a 
96-well assay plate and allowed 24 hours to adhere and grow with normal media 
conditions.  The media was removed and replaced with nanoparticle solutions using 
triplicates.  Nanoparticle solutions contained 1, 10, 25, 50, and 100 µg/mL of 
nanoparticles. Controls consisted of NP-NH2 and heparin (MW≈3,000 g/mol, MP 
Biomedicals) at concentrations of of 6.25, 25, 100, 400, 1600, and 3200 µg/mL.  Cells 
were incubated with experimental conditions for 48 hours. Experimental media was 
removed, and cells were washed with PBS three times to remove nanoparticles. Assays 
were performed using 1:5 ratio of the CellTiter AQueous One Solution Reagent diluted in 
PBS.  The assay was allowed to proceed for 2 hours at 37°C and 5% CO2. Absorbance of 
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the formazan product was read at 490 nm using a microplate reader. Presented cell 
proliferation represents absorbance normalized to the 0ug/mL PBS control. 
 
Live/Dead 
 Cells were seeded at 25,000 cells/well into a 24-well assay plate and allowed 3 
days to adhere and grow with normal media conditions.  The media was removed and 
replaced with nanoparticle solutions.  Nanoparticle solutions contained 1, 10, 25, 50, and 
100 µg/mL of nanoparticles. Heparin (MP Biomedicals) concentrations of 6.25, 25, 100, 
400, 1600, and 3200 µg/mL were also tested to determine inhibitory effects of the native 
molecule.  Cells were incubated with experimental conditions for 48 hours.  Following 
experimental treatment, a negative control was created by treatment with 70% ethanol for 
30 minutes at room temperature.  All cells were washed three times with PBS (MP 
Biomedicals).  Using a Live/Dead Viability/Cytotoxicity kit (Life Technologies), cells 
were incubated for 30 minutes with 2µM calcein acetoxymethyl and 4µM ethidium 
homodimer-1 diluted in PBS.  Cells were imaged with fluorescent microscopy, and 
fluorescence was measured using a microplate reader. Presented cell viability represents 
fluorescence normalized to the 0ug/mL PBS control. 
 
Prussian Blue Stain 
 The cellular uptake of nanoparticles was characterized with a Prussian Blue Stain 
kit (Polysciences). Cells were seeded at 5,000 cells/well into a 96-well assay plate and 
allowed 24 hours to adhere and grow with normal media conditions. The media was 
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removed and replaced with nanoparticle solutions using duplicates.  Cells were treated 
with media containing 1, 10, and 100 µg/mL of nanoparticles for 2 hours. Equal amounts 
of 4% potassium ferrocyanide and 4% hydrochloric acid were mixed to create a working 
solution. Cells were covered with the working solution for 10 minutes after which the 
solution was replaced for another 10-minute incubation. The cells were washed with PBS 
before counterstaining with Nuclear Fast Red for 3 minutes. Phase contrast images were 
taken using an Olympus CKX41 microscope. 
 
Immunofluorescence Staining 
 Immunofluorescence staining was performed to stain the smooth muscle alpha-
actin to determine if there is a phenotypic change based on the alpha-actin content and 
fiber distribution. Cells were seeded at 2,000 cells/well into a 96-well assay plate and 
allowed 24 hours to adhere and grow with normal media conditions. The media was 
removed and replaced with nanoparticle solutions using duplicates.  Nanoparticle 
solutions contained 1 and 10 µg/mL of nanoparticles. Cells were treated with the 
experimental conditions for 48 hours, then fixed with 4% paraformaldehyde (Sigma) for 
10 minutes and washed 3 times with PBS. Permeabilization occurred for 15 minutes with 
PBS / 0.01M glycine (Acros Organics) / 0.1% Triton X-100 (Sigma) and blocked with 
5% BSA/PBS followed by 5% donkey serum /1% BSA/PBS. The cells were incubated 
overnight at 4°C with primary antibody rabbit polyclonal to alpha smooth muscle actin 
(Abcam ab5694) in 1% BSA/PBS. Next, the cells were washed twice with 1% BSA/PBS 
followed by 5% donkey serum /1% BSA/PBS. Secondary antibody, Donkey anti-Rabbit 
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IgG (H+L) Secondary Antibody conjugated with Alexa Fluor® 488  (Invitrogen A21206) 
was diluted 1:100 in PBS and incubated with samples for 2 hours. Cells were washed 
with 1% BSA/PBS followed by pure PBS before staining for nuclei with DAPI at 300 
nM diluted in PBS. Cells were washed a final time with PBS before fluorescent imaging 
with the EVOS FL Imaging System. 
 
Statistical Analysis 
Statistical analysis was performed in R Studio. MTS and Live/Dead relative 
viabilities were tested for the equal variance assumption to use the Student t-test. If 
groups failed the equal variance test, then Welch Two Sample t-test was used. For 
comparison of multiple groups, the assumption of equal variance was tested using the 
Bartlett test of homogeneity of variances and Fligner-Killeen test of homogeneity of 
variances. One-way analysis of variance (ANOVA) followed by Tukey’s Honestly 
Significant Difference (HSD) test was performed to test for statistical significance. 
Results were considered significant for p < 0.05. 
 
5.4 Results 
Heparin coated nanoparticles inhibited the proliferation of VSMCs in a dose 
dependent fashion measured by relative MTS absorbance shown in Figure 5.1. Based on 
the morphology (images not shown) and MTS absorbance, control amine terminated 
nanoparticles resulted in cell death at all concentrations (p < 0.001). Heparin 
nanoparticles produced a significant decrease in VSMC proliferation at 1 µg/mL (p < 
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0.05) with increasing inhibition as the concentration increased up to 100 µg/mL. At 100 
µg/mL, the effects of heparin nanoparticles become indistinguishable from that of the 
amine nanoparticles. Based on the DMMB assay to determine heparin loading from 
Chapter Four, 1 µg of nanoparticle was coated with 0.976 µg of heparin. 
 
As a second measure of cell viability, Live/Dead was used to both quantitative 
and qualitatively compare with the MTS results. It is important to note that the 
nanoparticles used in the Live/Dead experiment are from a different batch than all other 
Figure 5.1. MTS relative viability of VMSCs after 48 hours of treatment with nanoparticles. 
Note: 1 µg of Fe3O4 is equivalent to 0.976 µg of heparin. * Denotes statistical significance 
relative to 0 µg/mL (p<0.05) 
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experiments described in this paper. This batch of nanoparticles was loaded with 2.8896 
µg of heparin per µg of nanoparticle. As seen in Figure 5.2, concentrations greater than 
10 µg/mL of heparin nanoparticles reduced relative cell viability (p < 0.005). Amine 
terminated nanoparticles significantly lowered cell viability at 25 µg/mL (p < 0.005). 
These values are consistent with the fluorescent images seen in Figure 5.3.  At 1 µg/mL 
for both nanoparticles, the live cells (shown in green) appear consistent in number and 
morphology with that of the positive control. At the critical concentration of 25 µg/mL 
Figure 5.2 Live/Dead relative viability of VMSCs after 48 hours of treatment with 
nanoparticles. Note: 1 µg of Fe3O4 is equivalent to 2.8896 µg of heparin. * Denotes 
statistical significance relative to 0 µg/mL (p<0.05) 
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and beyond, viable cells no longer exist shown by a noticeable absence of cells live or 






























































































































































Previously, experiments testing a range of concentrations of heparin (0-3200 
µg/mL) have shown to inhibit proliferation of VSMCs at concentrations as low as 25 
µg/mL [31]. For comparison, the same concentration range was tested with MTS and 
Live/Dead in this paper. Shown in Figure 5.4 and Figure 5.5, the heparin used in this 
experiment did not produce any significant change in VSMCs at any concentration. 
Observation of the fluorescent images, Figure 5.6, shows no difference in cell number or 
phenotype supporting the quantitative measurements of the MTS and Live/Dead assays. 
 
   
Figure 5.5 MTS and Live/Dead relative viability of VMSCs after 48 hours of 






















































































































































































































































































Prussian Blue staining was used to determine the fate of nanoparticles after 2 
hours. The Prussian Blue stain is a histochemical reaction that marks deposits of ferric 
iron in bright blue and is used to visualize cellular uptake of magnetite nanoparticles [32-
34]. Seen in Figure 5.7, treatment with amine terminated nanoparticles produces a 
noticeable change in phenotype with the formation of many vesicles (indicated in red 
arrows). Close examination of cells treated with 1 and 10 µg/mL amine nanoparticle 
shows dark blue staining in the vesicles suggesting presence of nanoparticles. After only 
2 hours of treatment, 100 µg/mL of amine particle proved toxic leading to fragmentation 
of cells, which resulted in an absence of cells in images. Heparin nanoparticles at any 
tested concentration do not appear to produce any phenotypic change observable with 
phase contrast microscopy 
Alpha smooth muscle actin is one of the markers commonly used to indicate a 
VSMC lineage towards either the synthetic or contractile phenotype [35-37]. VSMCs in 
the contractile phenotype have a spindle shape with contractile apparatuses aligned into 
fibers [38]. We observed the alpha smooth muscle actin content of VSMCs using 
immunofluorescence, Figure 5.8.  It is immediately obvious that the control amine 
terminated particle disrupted normal cell behavior resulting in cell fragmentation. 
Interestingly, this process seems to remove even the nuclei (shown in blue).  The 
synthetic phenotype can be observed in the Figure 5.8.a with a rhomboid shake and 
randomly oriented fibers. VSMCs subjected to heparin nanoparticles appear to have a 
more organized actin distribution and assume the spindle shape associated with the 






































































































































 Before heparin coated magnetic nanoparticles can be used in a clinical setting, 
there must be many tests to determine the optimal dosing concentrations and their effects. 
This study shows a first step towards this goal. As mentioned in the results, two different 
batches of nanoparticles were used in this study, and the loading of heparin per 
nanoparticle varied widely from batch (see Chapter Four for full details of heparin 
concentration determination). Heparin nanoparticles in the Live/Dead study were loaded 
with 2.8896 µg / µg of nanoparticle, while all other studies were loaded with 0.976 µg of 
heparin / µg of nanoparticle. Heparin has one of the highest charge density of any known 
biological molecule due to the multitude of sulfate and carboxylic acid groups [39]. This 
3-fold difference has the potential to leave a huge impact on the results of the studies. 
 The first step to evaluation of the potential for use in the clinic is determination of 
anti-proliferative/cytotoxic effects. In this study, we used MTS and Live/Dead assays to 
measure these characteristics. As shown in Figure 5.1, the anti-proliferative effects of 
heparin nanoparticles appear to follow a dose dependent fashion, which is indicative of 
potential future use. Unfortunately, the Live/Dead results do not match up with the MTS 
results.  As seen in Figure 5.2, the Live/Dead study shows a reversal of the trend shown 
from the MTS assay.  The previously explained excess heparin loading could explain 
their toxicity. The plasma membrane of a cell is covered with proteins, which require a 
specific conformation to function. One possible explanation is bringing a loaded heparin 
nanoparticle (ie. a highly negatively charged particle) in contact with many surface 
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proteins at once results in disruption of many membrane proteins, which could trigger 
cell death. 
Further evidence for this theory is supported by the fact that heparin alone did not 
shown any inhibition of proliferation at up to 3.2 mg/mL. Previous studies have shown 
significant changes in cell proliferation at concentrations as low as 25 µg/mL [31]. 
Although, it has been shown that the effects of heparin are dependent on the commercial 
brand of heparin [40]. Partial explanation for this variance comes from the fact that it has 
been shown that the anti-proliferative effects of heparin depend on very complex 
mechanisms involving the degree and location of sulfate groups [41]. 
Characterization of the fate of the nanoparticle is an important aspect of 
biocompatibility studies. Through Prussian Blue in Figure 5.7, we see support for the 
cellular uptake of amine particles. This appears to be consistent with other work that 
shows positively charged nanoparticles have greater cellular uptake than negatively 
charged particles [42]. Our results support a previous hypothesis that more positive 
nanoparticles have a greater affinity to the negatively charged cell bilayer membrane [28] 
causing to increased interactions and toxicity.  
 Based on the toxicity data (MTS), the optimal dosing appears to be at 10 µg/mL 
nanoparticle (1 µg/mL heparin) where we observed a 40% reduction in relative cell 
proliferation. A previous study has required 1600 µg/mL heparin to achieve this level of 
anti-proliferative effects [31]. It is plausible that proliferation inhibition occurs at this 
lower dosing than typical literature values due to the increased localized concentration 
from a single nanoparticle interacting with a cell. From Chapter Four, we know that 1 
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nanoparticle contains approximately 7,300 heparin molecules. Therefore, we may have 
achieved induction of a possible phenotypic shift observable by the distribution of alpha 
smooth muscle actin stained in Figure 5.8. While quantitative measurements were outside 
the scope of this study, there appears to be an increase in the number of spindle shaped 
cells with aligned actin fibers after treatment with 1 µg/mL and 10 µg/mL heparin 
nanoparticle. These features are indicative of the contractile phenotype and suggest that 
the use of heparin nanoparticles may be tool in the prevention of neointimal hyperplasia.  
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CONCLUSIONS AND RECOMMENDATIONS 
 
6.1 Conclusions 
 Clinicians have been battling neointimal hyperplasia for decades. Significant 
gains have been made into understanding the underlying mechanism. There has been 
clinical progress with the acceptance of drug eluting-stents. However as it stands with 
current technology, stents have problems leaving the room open for innovative solutions. 
Nanoparticles have shown great promise in a variety of applications. In particular, 
magnetic nanoparticles have shown great promise for the biomedical field. This research 
describes the application of magnetic nanoparticles to inhibit neoinimtal hyperplasia. 
 In our first study, we demonstrated successful synthesis of a magnetic 
nanoparticle tailored to a specific range. The importance of nanoparticle size in 
biomedical applications cannot be underestimated, and we consider the nanoparticle size 
distribution between 20 and 30 nm to be a great success. Heparin was chosen as the drug 
of interest as it induces duel effects of anticoagulation and antiproliferation. We 
successfully attached heparin to a nanoparticle that we have previously shown to be 
biocompatible. Although, variability in the synthesis process led to differences in amount 
of heparin loaded on each batch of nanoparticles, the results successfully demonstrate the 
capacity to create a heparin coated magnetic nanoparticle. 
 Our second study describes the initial testing to determine VSMC proliferation 
and toxicity in response to the synthesized particles. An ideal outcome would be a 
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reduction in cell numbers without induced cell death. Rather, VSMCs would undergo a 
phenotypic shift from the synthetic to the contractile phenotype. Depending on the batch 
of nanoparticles used, we observed either inhibition of proliferation or cell death, which 
we attribute to the to the 25 fold difference in heparin loading between the batches. This 
study is promising in that the low concentration of heparin nanoparticles led to a 
reduction in cell number without any noticeable negative change in cell morphology.  
Rather, we observed a possible change in actin distribution, which would be indicative of 
the contractile phenotype.  
 
6.2 Recommendations 
Taking both studies together, these results demonstrate successful synthesis of 
heparin-coated nanoparticles and give indication for future investigation. Removal of 
heparin loading variability seen in our studies should be the first step for future work. Our 
results support that the effects of heparin nanoparticles will be concentration dependent; 
therefore, it will be critical to determine the optimal dosing range to inhibit proliferation. 
It is likely that this range will depend on the concentration of both bound heparin and 
nanoparticles in solution. Furthermore, the phenotype of VSMCs after treatment will 
need to be assessed to determine if this treatment is likely to produce long-term effects by 
induction of the contractile phenotype. The phenotype change should be characterized in 
terms of gene/protein expression and mechanical properties in terms of Young’s 
Modulus. 
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To fully evaluate the effects of these nanoparticles, it will be important to add 
studies characterizing the effects of alcohol terminated particles following the ligand 
exchange in Chapter Four. Furthermore, it should be noted that all particles should be run 
through the water column immediately prior to cellular testing. In addition, the effects of 
these particles will need to be evaluated on other cell lines, particularly endothelial cells 
due to their proximity to VSMCs and cells that can be found throughout the body (ie. 
fibroblast) to evaluate potential systemic toxicity. 
The whole premise of this treatment relies on the ability to keep these magnetic 
nanoparticles concentrated while under pulsatile blood flow. This capability will depend 
largely on the synthesis of the nanoparticles; therefore, it may be necessary to adjust the 
synthesis method to attain the optimal particle size. With the optimal particle, the 
efficiency will have to be evaluated in animal studies. There remains much to be 
understood before this treatment can be used in a clinical setting; however, the results of 















Appendix A: Fe Determination Protocol – Up to 400 µg Fe 
(Revised 2/5/14) 
6th Revision 
Iron Solution Preparation: 
1. Obtain desired iron sample for test. 
2. Transfer 5-8 µL for concentrated samples or 100 µL for dilute samples to a 10 mL 
volumetric flask with a calibrated 10 µL pipette. Note: Use one of the short-
necked flasks to allow the pipette to reach the bottom of the flask. 
3. Dissolve the iron in the flask with approximately 0.2mL of concentrated HCl. 
4. Once all the iron has dissolved (about 15 sec), fill the volumetric flask with 
deionized water to the 10 mL mark. This is the iron stock solution. Using the 
ground glass stopper, mix by inverting the 10 mL volumetric flask 3 times. 
5. Transfer the solution from the volumetric flask to a disposable 15 mL centrifuge 
tube. Make sure the solution is well-mixed. 
 
Sample Preparation: 
*Note: Glassware is stored in the drying oven and should be rinsed at least 2X with 
deionized water following use. 
1. Using the calibrated 1 mL pipette, transfer 0 (blank), 0.5, 1, 1.5, 2, and 2.5 mL of 
iron stock solution to several 15 mL centrifuge tubes.  Label each centrifuge tube 
with these amounts.  These may vary.  Blank will include the following solution 
with the exception of iron. 
2. Dilute the iron solution in each centrifuge tube to approximately 6 mL with 
deionized water. 
3. To develop the color:    
a. Add 0.2 mL of hydroxylamine hydrochloride solution1 to each centrifuge 
tube and swirl to mix.  
b. Add 0.5 mL of 1,10-phenanthroline solution2 to each centrifuge tube.  
Mix. 
c. Add 0.75 mL of the ammonium acetate-acetic acid solution to each 
centrifuge tube (including the blank). 
d. Bring the volume of each centrifuge tube to 10 mL with nanopure (DI) 
water using a pipette.  Mix well by inverting the centrifuge tubes. 
4. Transfer about 3 mL from each flask to disposable PMMA cuvettes. Transfer the 




1. Measure all samples using the UV-Vis spectrophotometer 
2. For each sample record the absorbance at 511nm (the Fe peak) and at 690nm (the 
baseline) 
3. Once recorded, subtract the 690 nm absorbance from the 511 absorbance. This 
will be the value you insert for your absorbance into the iron determination 
spreadsheet. 
Cleaning the Volumetric Flask: 
1. After stock solution is made and transferred to a 15 ml centrifuge tube, add about 
3 ml of conc. HCl to the volumetric flask. 
2. Swirl it around for about 30 seconds and dispose of the acid. 
3. Rinse 2x with the water in the fume hood. 
4. Bring out of the fume hood and rinse 2x with DI water. 




*Note:   If a number does not pass the Grubb’s test in Excel Iron Determination: 
a. Re-enter the number in the column for the Grubb’s test in order to eliminate 
original equation. 
b.  Delete corresponding number in the µg/100mL column. 
c.  Highlight the row in red. 
 
*Note:   
1Hydroxylamine hydrochloride solutions (100 g/L)—dissolve 1 g of hydroxylamine 
hydrochloride in 10 mL nanopure water. 
21,10-phenanthroline solution (3 g/L)—dissolve 0.3 g of 1,10-phenanthroline 
monohydrate in 10 ml of methanol and dilute to 100 ml with nanopure water. 
3Ammonium acetate-acetic acid solution—dissolve 10 g of ammonium acetate in about 
60 mL of water, add 20 mL of glacial acetic acid, and diluted to 100 mL with nanopure 
water. 
 
a Method Title “Fe Determination” subject to change.  Reference: ASTM, E 394-0  
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Appendix B: DMMB Assay  
Written by: Alex Lindburg-MBEM Lab 
Updated: Elliott Mappus 3/4/15 
 
Materials 
1. Chondroitin sulfate (Sigma C4384) 




6. 96-well plates [with U-shaped bottoms] 
Directions 
1. 20 µL aliquots of media in triplicate should be used for analysis. 
2. The sample with the GAG highest concentration should be tested so an 
appropriate dilution can be made [See Note 3]. 
3. A standard curve should be made for comparison of media to solutions of known 
chondroitin sulfate concentrations. Make a working solution of 100 µg/mL by 
adding 2.0 mg of CS powder to 20 mL of PBS. 
 
Working                   Final 
Solution (µL)                         PBS (µL)      Concentration (µg/µL)      
0              200       0                                         
25              175       12.5                                    
50              150       2.5   
100              100       50                                        
150                         50       75  
200              0       100  
 
4. 180 µL of DMMB is added to each well using a multi-channel pipet 
5. Shake samples for 5 seconds 
6. The absorbance at 530 nm is measured immediately with a microtiter plate reader. 
Notes 
1. The working solution is made by dissolving 16 mg of DMMB dye in 1 L of water 
containing 3.04 g glycine , 2.37 g NaCl, and 95 mL of 0.1 M HCl. Filter the 
solution through Watman paper. Do not use if there is precipitate in it. 
2. The solution should be stored at room temperature in a brown bottle. The solution 
is stable for up to 2 months. 
3. The linear concentration of chondroitin sulfate in DMMB is limited to between 10 
and 50 µg/mL (0.2 and 1.0 µg in 20 µL of solution). 
Reference 
Mort, JS and PJ Roughley. Measurement of glycosaminoglycan release from cartilage 
explants. (2007) Methods in Molecular Medicine. 135, 201-209. 
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Appendix C: DMMB Standard Curves 
 
Comparison of heparin and chondroitin sulfate standard curves. The difference in slopes 






Appendix D: Isolating Vascular Smooth Muscle Cells 
1. Sacrifice rat using CO2 asphyxiation and cervical dislocation   
2. Remove aorta from subclavian origin to the diaphragm bifurcation and place in 
 DMEM with pen/strep   
3. Use tissue culture hood to remove all adventitia and connective tissue. All 
adventitia  must be removed to ensure you only attain VSMCs   
4. Cut vessel longitudinally so it lays flat and scrape off endothelium gently with 
scalpel  blade and rinse thoroughly in DMEM with pen/strep   
5. Cut the vessel into ~5 mm squares and place them in digestion solution that 
includes  5 ml DMEM, pen/strep (1%), Collagenase type II (final concentration 
175U/ml), and  10% FBS for 20 minutes   
6. Centrifuge at 500 rpm for 1 minute and remove the supernatant and wash the 
pellet  with DMEM containing pen/strep   
7. Resuspend the pieces in another digestion solution containing DMEM, pen/strep 
(1%)  Collagenase type II (final concentration 175U/ml), Elastase type III (final 
concentration 0.25 mg/ml) and 10% FBS for 1 hour. Be sure to shake the tube 
gently every 10 minutes until the vessel is gossamer thin. When the vessels are 
dissolved stop the digestion by diluting with equal volume of DMEM with 
pen/strep and 20% FBS   
8. Centrifuge 1000 rpm for 5 minutes and remove the supernatant   
9. Suspend cells in DMEM with pen/strep and 20% FBS and place in T-25 flask and 
put in incubator (37C, 5% CO2). Don’t change media for 72 hours as cells need 
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sufficient time to adhere to flask.   
10. Maintain the cells using DMEM with 20% FBS and pen/strep until cells reach P4 
then use 10% FBS   
 
